Roth Capital Issues Pessimistic Outlook for BRTX Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Stock analysts at Roth Capital dropped their FY2028 EPS estimates for shares of BioRestorative Therapies in a research note issued on Monday, February 10th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of $5.24 for the year, down from their prior estimate of $5.40. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ FY2029 earnings at $6.93 EPS.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.30 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%.

BioRestorative Therapies Price Performance

Shares of NASDAQ BRTX opened at $2.39 on Tuesday. The company has a 50 day simple moving average of $1.83 and a 200-day simple moving average of $1.67. The company has a market capitalization of $16.54 million, a P/E ratio of -1.56 and a beta of 62.62. BioRestorative Therapies has a 1 year low of $1.03 and a 1 year high of $2.55.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.